본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

American journal of hematology v.93 no.7, 2018년, pp.851 - 858  

Potent anti‐leukemia activities of humanized CD19‐targeted Chimeric antigen receptor T (CAR‐T) cells in patients with relapsed/refractory acute lymphoblastic leukemia

Cao, Jiang (Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China ) ; Wang, Gang (Cancer Institute, Xuzhou Medical University, Xuzhou, 221002, China ) ; Cheng, Hai (Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China ) ; Wei, Chen (Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China ) ; Qi, Kunming (Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China ) ; Sang, Wei (Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China ) ; Zhenyu, Li (Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China ) ; Shi, Ming (Cancer Institute, Xuzhou Medical Universi ) ; Li, Huizhong ; Qiao, Jianlin ; Pan, Bin ; Zhao, Jing ; Wu, Qingyun ; Zeng, Lingyu ; Niu, Mingshan ; Jing, Guangjun ; Zheng, Junnian ; Xu, Kailin ;
  • 초록  

    Abstract Chimeric antigen receptor T (CAR‐T) cell therapy has shown promising results for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). The immune response induced by murine single‐chain variable fragment (scFv) of the CAR may limit CAR‐T cell persistence and thus increases the risk of leukemia relapse. In this study, we developed a novel humanized scFv from the murine FMC63 antibody. A total of 18 R/R ALL patients with or without prior murine CD19 CAR‐T therapy were treated with humanized CD19‐targeted CAR‐T cells (hCART19s). After lymphodepletion chemotherapy with cyclophosphamide and fludarabine, the patients received a single dose (1 × 10 6 /kg) of autologous hCART19s infusion. Among the 14 patients without previous CAR‐T therapy, 13 (92.9%) achieved complete remission (CR) or CR with incomplete count recovery (CRi) on day 30, whereas 1 of the 3 patients who failed a second murine CAR‐T infusion achieved CR after hCART19s infusion. At day 180, the overall and leukemia‐free survival rates were 65.8% and 71.4%, respectively. The cumulative incidence of relapse was 22.6%, and the nonrelapse mortality rate was 7.1%. During treatment, 13 patients developed grade 1‐2 cytokine release syndrome (CRS), 4 patients developed grade 3‐5 CRS, and 1 patient experienced reversible neurotoxicity. These results indicated that hCART19s could induce remission in patients with R/R B‐ALL, especially in patients who received a reinfusion of murine CAR‐T.


 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기